ArticleCell reports2021
Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 60 citations in OpenAlex.
- The evolution of display technologies for antibody drug discovery.Trends in biotechnology · 2026Review
- The adaptive immune receptors in a big data world.ImmunoHorizons · 2026Review
- Potent Monoclonal Antibodies Against Circulating Yellow Fever Virus Strains from Donors Immunized with the 17D Vaccine.The American journal of tropical medicine and hygiene · 2026Article
- Structural and Functional Characterization of Anti-SARS-CoV-2 Spike Monoclonal Antibodies Produced via Bicistronic Expression in CHO Cells.Antibodies (Basel, Switzerland) · 2025Article
- Comparative Analysis of Mammalian Adaptive Immune Loci Revealed Spectacular Divergence and Common Genetic Patterns.Molecular biology and evolution · 2025Article
- Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Optimized single-cell gates for yeast display screening.Protein engineering, design & selection : PEDS · 2025Article
- Beyond Single Clones: High-Throughput Sequencing in Antibody Discovery.Cold Spring Harbor protocols · 2025Article
- Backstage Heroes-Yeast in COVID-19 Research.International journal of molecular sciences · 2024Review
- Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review).Molecular medicine reports · 2024Review
- Two-dimensional high-throughput on-cell screening of immunoglobulins against broad antigen repertoires.Communications biology · 2024Article
- Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies.Cell reports. Medicine · 2024Article
- Fusing Peptide Epitopes for Advanced Multiplex Serological Testing for SARS-CoV-2 Antibody Detection.ACS bio & med chem Au · 2024Article
- Studying SARS-CoV-2 interactions using phage-displayed receptor binding domain as a model protein.Scientific reports · 2024Article
- Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including the emerging EG.5 lineages.PLoS pathogens · 2023Article
- Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site.Nature communications · 2023Article
- Cell activation-based screening of natively paired human T cell receptor repertoires.Scientific reports · 2023Article
- Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses.Nature reviews. Immunology · 2023Review
- Large-scale antibody immune response mapping of splenic B cells and bone marrow plasma cells in a transgenic mouse model.Frontiers in immunology · 2023Article
- Monoclonal antibody therapies against SARS-CoV-2.The Lancet. Infectious diseases · 2022Review
Corrections and comments
- Update of
Authors and funding
34 authors at 7 institutions in 3 countries.
Bailey B BanachBioengineering Graduate Program, University of Kansas, Lawrence, KS 66045, USA.
Gabriele CeruttiDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA.
Ahmed S FahadDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Chen-Hsiang ShenVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Matheus Oliveira De SouzaDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Phinikoula S KatsambaDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA.
Yaroslav TsybovskyElectron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Pengfei WangAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
Manoj S NairAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
Yaoxing HuangAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
Irene M Francino-UrdánizDepartment of Chemical and Biological Engineering, University of Colorado, Boulder, CO 80305, USA.
Paul J SteinerDepartment of Chemical and Biological Engineering, University of Colorado, Boulder, CO 80305, USA.
Matías Gutiérrez-GonzálezDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Lihong LiuAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
Sheila N López AcevedoDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Alexandra F NazzariVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Jacy R WolfeDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Yang LuoAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
Adam S OliaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
I-Ting TengVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Jian YuDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
Tongqing ZhouVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Eswar R ReddemDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA.
Jude BimelaDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA.
Xiaoli PanDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Bharat MadanDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Amy D LaflinDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Rajani NimraniaDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Kwok-Yung YuenState Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Department of Microbiology, Queen Mart Hospital, Hong Kong Special Administrative Region, China; Department of Clinical Microbiology and Infection Control, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Timothy A WhiteheadDepartment of Chemical and Biological Engineering, University of Colorado, Boulder, CO 80305, USA.
David D HoAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
Peter D KwongDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Lawrence ShapiroDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA; Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA. Electronic address: lss8@columbia.edu.
Brandon J DeKoskyBioengineering Graduate Program, University of Kansas, Lawrence, KS 66045, USA; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA; Department of Chemical Engineering, University of Kansas, Lawrence, KS 66045, USA. Electronic address: dekosky@ku.edu.
University of Kansas · USAaron Diamond AIDS Research Center · USNational Institutes of Health · USColumbia University · USUniversity of Colorado Boulder · USLeidos (United States) · USQueen Mary Hospital · CN
Funding
The influence of evolutionary landscapes on protective antibody developmentR01AI141452 · NIAID · UNIVERSITY OF COLORADO · PI WHITEHEAD, TIMOTHY ANDREW · 2019 to 2023
$2.8MComprehensive analysis of human adaptive immune receptors to elucidate correlates of Epstein-Barr virus disease suppressionDP5OD023118 · OD · UNIVERSITY OF KANSAS LAWRENCE · PI DEKOSKY, BRANDON JAMES · 2016 to 2022
$2.2MComprehensive molecular and functional analyses of anti-HIV-1 broadly neutralizing antibody repertoiresR21AI143407 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI DEKOSKY, BRANDON JAMES, FORREST, MARCUS LAIRD · 2019 to 2020
$435kProbing antigen specificity and response of autoimmune B cells in Neuromyelitis OpticaR21AI144408 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI DEKOSKY, BRANDON JAMES · 2019 to 2020
$417kCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS R01 AI141452NIAID NIH HHS R21 AI143407NIAID NIH HHS R21 AI144408NIH HHS DP5 OD023118
Abstract
Understanding mechanisms of protective antibody recognition can inform vaccine and therapeutic strategies against SARS-CoV-2. We report a monoclonal antibody, 910-30, targeting the SARS-CoV-2 receptor-binding site for ACE2 as a member of a public antibody response encoded by IGHV3-53/IGHV3-66 genes. Sequence and structural analyses of 910-30 and related antibodies explore how class recognition features correlate with SARS-CoV-2 neutralization. Cryo-EM structures of 910-30 bound to the SARS-CoV-2 spike trimer reveal binding interactions and its ability to disassemble spike. Despite heavy-chain sequence similarity, biophysical analyses of IGHV3-53/3-66-encoded antibodies highlight the importance of native heavy:light pairings for ACE2-binding competition and SARS-CoV-2 neutralization. We develop paired heavy:light class sequence signatures and determine antibody precursor prevalence to be ∼1 in 44,000 human B cells, consistent with public antibody identification in several convalescent COVID-19 patients. These class signatures reveal genetic, structural, and functional immune features that are helpful in accelerating antibody-based medical interventions for SARS-CoV-2.
Indexed as
AgedAngiotensin-Converting Enzyme 2AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntibody FormationBinding SitesB-LymphocytesChlorocebus aethiopsCOVID-19Cryoelectron MicroscopyHEK293 CellsHumansImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2B-cellbiotechnologyimmunityneutralizationpublic antibodySARS-CoV-2virologyyeast display
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.